Search Result

Results for "

her2-negative breast cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Apoptosis (1) Caspase (1) CDK (12) EGFR (1) Estrogen Receptor/ERR (2) Fluorescent Dye (1) Heme Oxygenase (HO) (1) Isotope-Labeled Compounds (3) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Photosensitizer (1) PSMA (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Steroid Sulfatase (1) Wnt (1)
By Research Areas:	Cancer (21) Infection (1) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: BCRP BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50767

Palbociclib Maximum Cited Publications 239 Publications Verification PD 0332991	CDK	Cancer
Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767C

Palbociclib hydrochloride 215+ Cited Publications PD-0332991 hydrochloride	CDK	Cancer
Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767A

Palbociclib monohydrochloride Maximum Cited Publications 239 Publications Verification PD 0332991 monohydrochloride	CDK	Cancer
Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-A0065

Palbociclib isethionate 230+ Cited Publications PD 0332991 isethionate	CDK	Infection Neurological Disease Cancer
Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-50767R

Palbociclib (Standard) PD 0332991 (Standard)	Reference Standards CDK	Cancer
Palbociclib (Standard) is the analytical standard of Palbociclib. This product is intended for research and analytical applications. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-112596

H3B-6545 3 Publications Verification	Estrogen Receptor/ERR	Cancer
H3B-6545 is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .

HY-112749

ME-344	Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Mitochondrial Metabolism Microtubule/Tubulin Caspase Apoptosis	Cancer
ME-344 is an Isoflavone. ME-344 increases mitochondrial ROS generation. ME-344 inhibits tubulin polymerization. ME-344 inhibits HO-1 and impacts its mitochondrial translocation. ME-344 induces Apoptosis through Caspase 3 activation. ME-344 synergizes with Vinblastine in leukemia cells. ME-344 displays anti-tumor activity against leukemia and lung tumor. ME-344 can be used in the research of lung cancer, acute myeloid leukemia, and HER2-negative breast cancer .

HY-D2309

IRDye700Dx (Maleimide)	Fluorescent Dye Photosensitizer	Cancer
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in *HER2*-positive breast cancer cells without causing damage to *HER2*-negative breast cancer cells .

HY-50767S

Palbociclib-d8 PD 0332991-d₈	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-117756

Piflufolastat DCFPYL	PSMA	Cancer
Piflufolastat (DCFPYL) can be used for the preparation of piflufolastat F 18 (DCFPyL F-18). Piflufolastat F-18 (DCFPyL F-18) is an ¹⁸F-labeled imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA). Piflufolastat can be used for imaging of prostate cancer .

HY-112596A

H3B-6545 hydrochloride 3 Publications Verification	Estrogen Receptor/ERR	Cancer
H3B-6545 hydrochloride is an oral, selective estrogen receptor covalent antagonist (SERCA) for the research of metastatic ER-positive, HER2-negative breast cancer .

HY-50767AR

Palbociclib monohydrochloride (Standard) PD 0332991 monohydrochloride (Standard)	CDK Reference Standards	Cancer
Palbociclib (monohydrochloride) (Standard) is the analytical standard of Palbociclib (monohydrochloride). This product is intended for research and analytical applications. Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-201330

GDC-4198 RGT-419B	CDK	Cancer
GDC-4198 (RGT-419B) is an orally active CDK4/2 inhibitor with desired degrees of selectivity against kinases such as CDK6, CDK9 and GSK3β. GDC-4198 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. GDC-4198 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer .

HY-50767B

Palbociclib dihydrochloride PD-0332991 dihydrochloride	CDK	Cancer
Palbociclib (PD 0332991) dihydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib dihydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767D

Palbociclib orotate PD 0332991 orotate	CDK	Cancer
Palbociclib (PD 0332991) orotate is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib orotate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib orotate can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-W654305

Palbociclib-d4 PD 0332991-d₄	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767S1

Palbociclib-d4 hydrochloride PD 0332991-d4 hydrochloride	Isotope-Labeled Compounds CDK	Cancer
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-P10792A

HYNIC-H6F	EGFR	Cancer
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in *HER2*-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in *HER2*-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of *HER2*-positive breast cancer in mouse models and allows evaluation of *HER2* expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .

HY-182755

Steroid sulfatase-IN-12	Steroid Sulfatase	Cancer
Steroid sulfatase-IN-12 is a steroid sulfatase inhibitor. Steroid sulfatase-IN-12 inhibits the activity of steroid sulfatase. Steroid sulfatase-IN-12 can be used in research related to hormone receptor-positive/HER2-negative breast cancer .

HY-P992103

Beruzatatug BNT326/YL202 Antibody	ADC Payload	Cancer
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .

IRDye700Dx (Maleimide)	Fluorescent Dyes
IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in *HER2*-positive breast cancer cells without causing damage to *HER2*-negative breast cancer cells .

Cat. No.	Product Name	Target	Research Area

HY-P10792A

HYNIC-H6F	EGFR	Cancer
HYNIC-H6F is a SPECT imaging probe with binding specificity for human epidermal growth factor receptor 2 (HER2) domain II (IC₅₀ = 11 nM). HYNIC-H6F accumulates in *HER2*-positive breast cancer xenografts via receptor-mediated uptake, while shows low uptake in *HER2*-negative breast cancer xenografts. HYNIC-H6F enables non-invasive detection of *HER2*-positive breast cancer in mouse models and allows evaluation of *HER2* expression levels without blocking interference. HYNIC-H6F can be used in breast cancer-related research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P992103

Beruzatatug BNT326/YL202 Antibody	ADC Payload	Cancer
Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against HER3. Beruzatatug can be used for the synthesis of ADCs, such as BNT326/YL202 .

Cat. No.	Product Name	Chemical Structure

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

HY-W654305

Palbociclib-d4
Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

Palbociclib-d4

Palbociclib-d₄ is deuterium labeled Palbociclib. Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC₅₀ values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC₅₀s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.